Showing 1291-1300 of 6983 results for "".
Testing for Persistent Atopic Dermatitis in Pediatric Patients
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37151/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains key considerations when testing for persistent atopic dermatitis in children.Psoriasis Therapeutics and Moving to Private Practice
https://practicaldermatology.com/series/the-practical-dermatology-podcast/program-name/35733/H.L. Greenberg, MD, discusses his recent Practical Dermatology article on the various benefits of different psoriasis therapeutics, and Tina Bhutani, MD, MAS, FAAD, joins Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the transition from academia to private practice and playLow-Nickel Diets Show Promise for Contact Dermatitis
https://practicaldermatology.com/conferences/maui-derm-2024/low-nickel-diets-show-promise-for-contact-dermatitis/20256/Matthew Zirwas, MD, discusses his experience with the “low-nickel diet” for patients who have systemic reactions to dietary nickel.What’s New for Treating Hyperhidrosis?
https://practicaldermatology.com/conferences/scale-2023/whats-new-for-treating-hyperhidrosis/20208/The treatment of hyperhidrosis has changed a lot over the years. Larry Green, MD, discusses some of the exciting innovations including targeted alkali thermolysis.An Inside Look at How Incyte is Addressing Unmet Needs of Patients with Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/an-inside-look-at-how-incyte-is-addressing-unmet-needs-of-patients-with-atopic-dermatitis/20156/Ahmad Naim, Vice President of US Medical Affairs at Incyte, discusses the challenges around atopic dermatitis (AD) management and how Incyte is utilizing its expertise in immunology to address unmet needs for patients.What to do if your practice’s social accounts are inactive
https://practicaldermatology.com/topics/practice-management/what-to-do-if-your-practices-social-accounts-are-inactive/20127/Social media is the can’t miss marketing platform of 2022. However, it has been around long enough that many businesses have already tried it and given up years ago. If you are among the many dermatology practices with an old, outdated, nearly inactive Facebook or other social accounts, check out thFinally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."Scientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P